Brain Health: Understanding the Alzheimer’s Disease Continuum

Alzheimer's Disease (AD) is one of the most urgent global health challenges, and with populations aging rapidly worldwide, the need for more effective interventions has never been greater. Despite scientific advances, most people are diagnosed after a significant cognitive decline has already occurred. Recent developments in blood-based biomarkers (BBBM) offer a promising avenue for detecting Alzheimer’s pathology years before clinical symptoms emerge. Early detection could open the door for earlier interventions, leading to improved patient outcomes and potentially lessening the long-term burden on health systems.

This event will explore the Alzheimer’s Disease continuum, focusing on the importance of early diagnosis and the potential role of blood-based biomarkers in detecting Alzheimer’s long before symptoms arise. Leading experts from various sectors—including medical science, patient advocacy, global health, and health economics—will discuss the value of early diagnosis, its integration into healthcare practices, and the broader social, economic, and policy implications.